Intercept Pharmaceuticals, Inc. Logo

Press releases

Date Title and Summary View
Toggle Summary Intercept to Present at Upcoming Conference
NEW YORK , March 26, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be participating in the
View HTML
Toggle Summary Intercept Announces Multiple New Ocaliva® (obeticholic acid) Data Presentations at the International Liver Congress™ 2018
Late-breaking presentation will feature the first clinical data from a biopsy-based substudy supporting obeticholic acid’s ability to reverse or stabilize fibrosis and cirrhosis in primary biliary cholangitis (PBC) patients NEW YORK , March 23, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals,
View HTML
Toggle Summary Intercept to Present at Upcoming Conference
NEW YORK , March 13, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the
View HTML
Toggle Summary Intercept Pharmaceuticals Reports Full Year and Fourth Quarter 2017 Financial Results and Provides Business Update
Worldwide Net Ocaliva ®   (obeticholic acid or OCA) full year 2017 net sales of $129.2 million , fourth quarter 2017 sales of $37.3 million U.S. Prescribing Information for Ocaliva ® updated to reinforce appropriate dosing in PBC patients with advanced cirrhosis Continuing to advance industry
View HTML
Toggle Summary Intercept Announces Phase 3 REVERSE Trial Evaluating OCA for the Treatment of NASH Patients with Compensated Cirrhosis
Results from REVERSE are intended to serve as the basis for seeking marketing approval of OCA for the treatment of NASH patients with compensated cirrhosis   REGENERATE and REVERSE pivotal trials expand Intercept’s leadership’s position in NASH NEW YORK , Feb.
View HTML
Toggle Summary Intercept to Report 2017 Full Year Financial Results on February 14 and Present at Upcoming Conferences
NEW YORK , Feb. 07, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its fourth quarter and
View HTML
Toggle Summary Intercept Announces Updated U.S. Prescribing Information for Ocaliva® (obeticholic acid) to Reinforce Appropriate Dosing in PBC Patients with Advanced Cirrhosis View HTML
Toggle Summary Intercept to Present at Upcoming Conference
NEW YORK, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the
View HTML
Toggle Summary Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development
NEW YORK, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Christian Weyer, M.D.,
View HTML
Toggle Summary Intercept Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
Worldwide net Ocaliva ® (obeticholic acid or OCA) 3Q 2017 sales of $40.9 million (including one-time increase of $4.1M in deferred net revenue ) Continuing to advance NASH Phase 3 program: REGENERATE trial in NASH fibrosis on track and NASH cirrhosis trial to initiate by year end 2017   Conference
View HTML